Via News Knowledge File

Merck & Co., Inc.

organization80% conf.·synced Sep 28, 2026

Pharmaceutical company based in Rahway, NJ, known as MSD outside US and Canada

sourced metrics

660

relationships

stated objectives

Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Price 52 Week High

156.45USD

Sep 25, 2026reference only

Stock Return Ytd

39.8%

Sep 25, 2026reference only

Price 52 Week Low

78.58USD

Sep 25, 2026reference only

Market Cap

367065796302USD

Sep 25, 2026reference only

Stock Price

148.78USD

Sep 25, 2026reference only

Shares Outstanding

2467171638.0shares

Jul 31, 2026reference only

Cost Of Revenue

4395000000.0USD

Jun 30, 2026reference only

Cash

6849000000.0USD

Jun 30, 2026reference only

Eps

-0.54USD_per_share

Jun 30, 2026reference only

Revenue

16607000000.0USD

Jun 30, 2026reference only

Rd Expense

9741000000.0USD

Jun 30, 2026reference only

Total Assets

129802000000.0USD

Jun 30, 2026reference only

Stockholders Equity

41933000000.0USD

Jun 30, 2026reference only

Net Income

-1335000000.0USD

Jun 30, 2026reference only

Operating Cash Flow

3918000000.0USD

Mar 31, 2026reference only

Capex

991000000.0USD

Mar 31, 2026reference only

Stated objectives

Enroll approximately 675 patients in KANDLELIT-007 Phase 3 trial

source

target: 675 patients stated

Evaluate progression-free survival as primary endpoint in PD-L1 TPS ≥1% patients in KANDLELIT-007

source

stated

Evaluate secondary endpoints including PFS in all patients, overall survival, objective response rate, duration of response, and safety in KANDLELIT-007

source

stated

Submit regulatory filings worldwide for KEYTRUDA + Padcev combination in muscle-invasive bladder cancer based on KEYNOTE-B15/EV-304 results

source

stated

Initiate second Merck-sponsored pivotal trial of zanzalintinib and belzutifan in RCC

source

stated

Full-year sales forecast

source

target: $64.5 billion to $65 billion by 2025-12-31 00:00:00stated

Full-year EPS forecast

source

target: $8.93 to $8.98 by 2025-12-31 00:00:00stated

Improving outcomes and addressing significant unmet needs for patients with hematologic neoplasms and malignancies

source

stated

Become the premier research-intensive biopharmaceutical company in the world

source

stated

Deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals

source

stated

Relationship graph · 660 connections

Developed by

267

Competes with

Employs

acquired by

Partnered with

Covered by

regulates

headquartered in

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →